Daily biotech dealflow + market tape in 5 minutes — for VC, BD&L, and public biotech investors.
Newsletter
May 28, 2026
•
3 min read
$1.3B for Apogee with zero dilution, a hepatitis B functional cure from GSK, and a faster FDA clock for Sanofi.
May 26, 2026
Lilly posts early Verve data, ASCO names to watch sharpen, and neuromuscular FDA clocks speed up.
May 22, 2026
Lilly's retatrutide hits Phase 3 in obesity, Biogen and Denali scrap BIIB122, and Retro lands at a $1.8B valuation.
May 21, 2026
BioMarin lands Phase 3 data, Lilly adds delivery tech, and cAMPfield puts up a $180M Series A.
May 20, 2026
4 min read
Paragon's Mentari hits Nasdaq via reverse merger with $290M PIPE, Relay scores in vascular anomalies and tags a $175M raise, and Regeneron seeds a $2.3B Helicon bet at Parabilis.
May 19, 2026
Hansa’s licensing win, private cash, and a softer biotech tape set the tone.
May 18, 2026
Candel adds follow-up ahead of filing, Aardvark hits a hold, and FDA leadership churn clouds the setup.
May 15, 2026
Diranersen lives, RGX-202 hits with a safety asterisk, and Alumis tees up a strategic review.
May 14, 2026
Fosun pays $60M to option AriBio's AR1001, Ipsen debuts corabotase as first-in-class RNI, and Altimmune queues twin pemvidutide catalysts.
